This year however as a result of a rapid anddramatic 15 strengthening of the U

Beclomethasone dipropionate (BDP) is a highlypotent, topically active corticosteroid that has a local effect oninflamed tissue. orBec(R) is formulated for oral administration as asingle product consisting of two tablets; one tablet is intended torelease BDP in the proximal portions of the GI tract, and the othertablet is intended to release BDP in the distal portions of the GI tract.In addition to issued patents and pending worldwide patent applicationsheld by or exclusively licensed to DOR, orBec(R) also benefits from orphandrug designations in the US and in Europe for the treatment of GI GVHD,which provide for seven and 10 years of post-approval market exclusivity,respectively.About GI GVHDGI GVHD is a debilitating and painful disease and constitutes an unmetmedical need. It is a common disorder among immunocompromised cancerpatients after receiving hematopoietic cell transplantation. Patients withmild-to-moderate GI GVHD typically develop symptoms of anorexia, nausea,vomiting and diarrhea. If left untreated, GI GVHD can progress toulcerations in the lining of the GI tract, and in its most severe form,can be fatal.About DOR BioPharma, Inc.DOR BioPharma, Inc. (DOR) is a late-stage biopharmaceutical companydeveloping products to treat life-threatening side effects of cancertreatments and serious gastrointestinal diseases, and vaccines for certainbioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasonedipropionate or BDP), is a potent, locally acting corticosteroid beingdeveloped for the treatment of gastrointestinal Graft-versus-Host disease(GI GVHD), a common and potentially life-threatening complication ofhematopoietic cell transplantation.

DOR expects to begin a confirmatoryPhase 3 clinical trial of orBec(R) for the treatment of GI GVHD in 1H2009. orBec(R) is also currently the subject of an NIH-supported, Phase 2,randomized, double-blind, placebo-controlled trial in the prevention ofacute GVHD. Oral BDP may also have application in treating othergastrointestinal disorders characterized by severe inflammation.Additionally, DOR has a Lipid Polymer Micelle (LPM(TM)) drug deliverytechnology for the oral delivery of leuprolide for the treatment ofprostate cancer and endometriosis.Through its Biodefense Division, DOR is developing biomedicalcountermeasures pursuant to the Project BioShield Act of 2004. DOR'sbiodefense products in development are recombinant subunit vaccinesdesigned to protect against the lethal effects of exposure to ricin toxin,botulinum toxin and anthrax. Statements that are nothistorical facts, such as "anticipates," "believes," "intends," or similarexpressions, are forward-looking statements. These statements are subjectto a number of risks, uncertainties and other factors that could causeactual events or results in future periods to differ materially from whatis expressed in, or implied by, these statements.

Important factors which may affectthe future use of orBec(R) for gastrointestinal GVHD include the risksthat: the FDA's requirement that DOR conduct additional clinical trialsto demonstrate the safety and efficacy of orBec(R) will take asignificant amount of time and money to complete and positive resultsleading to regulatory approval cannot be assumed; DOR is dependent on theexpertise, effort, priorities and contractual obligations of thirdparties in the clinical trials, manufacturing, marketing, sales anddistribution of its products; orBec(R) may not gain market acceptance ifit is eventually approved by the FDA; and others may develop technologiesor products superior to orBec(R). These and other factors are describedfrom time to time in filings with the Securities and Exchange Commission,including, but not limited to, DOR's most recent reports on Forms 10-Qand 10-KSB. Unless required by law, DOR assumes no obligation to updateor revise any forward-looking statements as a result of new informationor future events.Company Contact:Evan MyrianthopoulosChief Financial Officer(609) 538-8200 BioPharma, Inc.850 Bear Tavern Road, Suite 201Ewing, NJ 08628Copyright 2009, Market Wire, All rights reserved.-0-. UTICA, NY, Jan 05 (MARKET WIRE) CONMED Corporation (NASDAQ: CNMD) announced today that its fourth quarter2008 sales will be approximately 9 lower than previously anticipated dueto unfavorable foreign currency exchange fluctuations and lower thananticipated sales volumes for capital equipment.Fourth quarter 2008 sales are expected to approximate $176 - $178 million,a decrease of approximately 7 from fourth quarter 2007 sales, whichincluded approximately $10 million of integrated systems installations atan unusually large number of hospital customers that chose to delayinstallations until late in that year. Full year 2008 sales are expectedto approximate $739 - $741 million, an increase of approximately 6.5 over2007 sales."Usually, the Company's sales in the fourth quarter of each yearexperience a sequential increase from the seasonal effects of the thirdquarter's summer months. This year, however, as a result of a rapid anddramatic 15 strengthening of the U.S. dollar adversely affecting foreignsales in the fourth quarter, and due to cash conservation measures amongcertain hospital customers causing a reduction from anticipated salesvolumes for our capital equipment, the Company's fourth quarter saleswill be lower than our previous estimates," said Mr Joseph J.